Obach R S, Baxter J G, Liston T E, Silber B M, Jones B C, MacIntyre F, Rance D J, Wastall P
Department of Drug Metabolism, Pfizer Central Research, Groton, Connecticut 06340, USA.
J Pharmacol Exp Ther. 1997 Oct;283(1):46-58.
We describe a comprehensive retrospective analysis in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclinical pharmacokinetic data and/or in vitro metabolism data were assessed. The prediction methods examined included both methods from the scientific literature as well as some described in this report for the first time. Four methods were examined for their ability to predict human volume of distribution. Three were highly predictive, yielding, on average, predictions that were within 60% to 90% of actual values. Twelve methods were assessed for their utility in predicting clearance. The most successful allometric scaling method yielded clearance predictions that were, on average, within 80% of actual values. The best methods in which in vitro metabolism data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on average, within 70% to 80% of actual values. Human t1/2 was predicted by combining predictions of human volume of distribution and clearance. The best t1/2 prediction methods successfully assigned compounds to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time. In addition, correlations between human t1/2 and t1/2 values from preclinical species were also generally successful (72-87%) when used to predict human dosing regimens. In summary, this retrospective analysis has identified several approaches by which human pharmacokinetic data can be predicted from preclinical data. Such approaches should find utility in the drug discovery and development processes in the identification and selection of compounds that will possess appropriate pharmacokinetic characteristics in humans for progression to clinical trials.
我们描述了一项全面的回顾性分析,其中评估了几种从临床前药代动力学数据和/或体外代谢数据预测人体药代动力学参数的方法的能力。所研究的预测方法包括科学文献中的方法以及本报告首次描述的一些方法。研究了四种预测人体分布容积的方法。其中三种具有高度预测性,平均预测值在实际值的60%至90%范围内。评估了十二种预测清除率的方法的效用。最成功的异速生长比例缩放法得出的清除率预测值平均在实际值的80%以内。将人肝微粒体的体外代谢数据缩放到体内清除率值的最佳方法得出的预测清除率值平均在实际值的70%至80%范围内。通过结合人体分布容积和清除率的预测来预测人体t1/2。最佳的t1/2预测方法在70%至80%的时间内成功地将化合物分配到适当的给药方案类别(例如,每日一次、每日两次等)。此外,当用于预测人体给药方案时,人体t1/2与临床前物种的t1/2值之间的相关性通常也很成功(72 - 87%)。总之,这项回顾性分析确定了几种可从临床前数据预测人体药代动力学数据的方法。这些方法在药物发现和开发过程中,对于识别和选择在人体中具有适当药代动力学特征以推进到临床试验的化合物应具有实用价值。